Mymd Pharmaceuticals (NASDAQ:QCLS) Stock Price Up 5.4% – Time to Buy?

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) shares shot up 5.4% on Monday . The company traded as high as $2.81 and last traded at $2.75. Approximately 75,025 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 190,927 shares. The stock had previously closed at $2.61.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on QCLS. Wall Street Zen raised Mymd Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings assumed coverage on shares of Mymd Pharmaceuticals in a report on Wednesday, May 13th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Mymd Pharmaceuticals Stock Up 4.0%

The stock has a market cap of $11.93 million, a P/E ratio of -0.14 and a beta of 2.16. The business’s fifty day moving average price is $3.65.

Mymd Pharmaceuticals (NASDAQ:QCLS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.